# VHL (Von Hippel-Lindau): Hypoxia-Inducible Factor (HIF) Degradation and Clear Cell Renal Carcinoma


## Key Takeaways

- Loss of the *VHL* gene function is the primary genetic event in Von Hippel-Lindau syndrome and the initiating step in most clear cell renal cell carcinomas (ccRCC), leading to the stabilization and nuclear accumulation of Hypoxia-Inducible Factor-alpha (HIF-α).
- The pVHL protein acts as the substrate recognition subunit of an E3 ubiquitin ligase complex, targeting hydroxylated HIF-α for proteasomal degradation under normoxic conditions; its functional loss disrupts this oxygen-sensing mechanism.
- Beyond HIF degradation, pVHL plays critical HIF-independent roles in microtubule stabilization, primary cilia maintenance, and extracellular matrix remodeling, all of which are compromised in VHL-deficient cancers.
- Pathogenic *VHL* mutations, particularly missense variants in the beta and alpha domains, exhibit strong genotype-phenotype correlations, dictating the risk and spectrum of associated tumors like ccRCC, hemangioblastomas, and pheochromocytomas.
- Therapeutic strategies for VHL-associated ccRCC include HIF-2α inhibitors like Belzutifan, anti-angiogenic agents targeting VEGF, mTOR inhibitors, and immune checkpoint inhibitors, reflecting the multifaceted molecular pathology driven by VHL loss.

---

## Executive Summary & Key Metadata

The *VHL* gene encodes the substrate recognition component of an E3 ubiquitin ligase complex that constitutes the central oxygen-sensing machinery of the cell. Its functional loss is the defining genetic event in hereditary Von Hippel-Lindau syndrome and the initiating step in the majority of sporadic clear cell renal cell carcinoma (ccRCC). The protein product, pVHL, is a 213-amino-acid protein that assembles with Elongin B, Elongin C, Cullin-2, and Rbx1 to form the CBCVHL E3 ligase complex. Under normoxic conditions, pVHL binds to hydroxylated proline residues on the alpha subunit of Hypoxia-Inducible Factor (HIF-α), targeting it for polyubiquitination and proteasomal degradation. Under hypoxia, or when pVHL is mutated, HIF-α accumulates and translocates to the nucleus, driving a transcriptional program of angiogenesis, glycolysis, and cell proliferation. Beyond its canonical HIF-dependent role, pVHL exerts HIF-independent functions in microtubule stabilization, primary cilia maintenance, and extracellular matrix remodeling. The structural biology of pVHL, particularly the alpha and beta domains, has been extensively characterized, providing a framework for understanding the genotype-phenotype correlations that dictate the clinical spectrum of VHL disease.

| **Attribute** | **Value** |
| :--- | :--- |
| **HGNC Symbol** | VHL |
| **UniProt Accession** | P40337 |
| **Representative PDB ID** | 1LM8 |
| **Chromosomal Locus** | 3p25.3 |
| **Primary Molecular Function** | Substrate recognition subunit of an E3 ubiquitin-protein ligase complex; targets HIF-α for proteasomal degradation |
| **Disease & Pathology Associations** | Von Hippel-Lindau syndrome (OMIM #193300); Clear cell renal cell carcinoma (ccRCC); Hemangioblastoma; Pheochromocytoma; Pancreatic neuroendocrine tumors |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Genomic Architecture

The *VHL* gene is located on the short arm of chromosome 3 at cytogenetic band 3p25.3. The precise genomic coordinates (GRCh38/hg38) span from 10,141,378 to 10,153,778 on the forward strand, encompassing a total genomic length of approximately 12.4 kilobases (kb). The gene is relatively compact, containing three exons that produce a mature messenger RNA (mRNA) of approximately 4.7 kb, which includes a long 3' untranslated region (UTR) that is unusually large for a gene of this size.

The genomic organization is as follows:
- **Exon 1**: 716 base pairs (bp) of coding sequence, encoding the N-terminal portion of the protein including the entire beta domain and the start of the alpha domain.
- **Exon 2**: 117 bp of coding sequence, encoding a critical portion of the alpha domain.
- **Exon 3**: 352 bp of coding sequence, encoding the C-terminal region of the alpha domain and the Elongin C binding site.

The promoter region of *VHL* is characterized by a CpG island that spans the transcription start site (TSS) and extends into exon 1. This CpG island is a frequent target of aberrant hypermethylation in sporadic ccRCC, representing a key epigenetic mechanism of gene silencing that is mutually exclusive with intragenic mutations. The promoter lacks a canonical TATA box but contains multiple GC boxes that serve as binding sites for the transcription factor Sp1, which is essential for basal transcriptional activity. Additionally, there are binding sites for the transcription factors AP-2 and E2F1, which modulate expression in response to growth signals.

### 1.2 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) studies have identified several putative enhancer elements within the *VHL* locus. A distal enhancer located approximately 20 kb upstream of the TSS has been shown to interact with the promoter via chromatin looping, and this interaction is lost upon DNA methylation of the promoter region in cancer cells. The three-dimensional chromatin architecture of the 3p25.3 region is organized into a topologically associating domain (TAD) that contains *VHL* and the neighboring genes *BRK1* and *GCLC*. Disruption of this TAD boundary has been proposed as a mechanism that could contribute to dysregulation of *VHL* expression, although this remains an area of active investigation.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of the *VHL* gene generates multiple mRNA isoforms, although the functional significance of several of these remains incompletely defined. The primary transcript encodes the canonical 213-amino-acid pVHL30 protein (molecular weight ~24 kDa, but migrating at ~30 kDa on SDS-PAGE due to its acidic nature). A second well-characterized isoform, pVHL19, arises from translation initiation at an internal methionine codon at position 54 (Met54). This isoform lacks the N-terminal 53 amino acids, which includes a portion of the beta domain. pVHL19 retains the ability to bind HIF-α and Elongin C, and it can partially rescue HIF-α degradation in VHL-null cells, but it is deficient in some HIF-independent functions, such as the assembly of the primary cilium and the regulation of microtubule dynamics.

Additional splice variants have been described, including a form that skips exon 2, which produces a truncated protein that is typically non-functional and subject to rapid degradation. The relative expression of these isoforms is tissue-specific, with pVHL30 being the predominant form in most tissues, while pVHL19 is more abundant in the kidney and liver. The 5' UTR of the *VHL* mRNA contains an internal ribosome entry site (IRES) that permits cap-independent translation under conditions of cellular stress, ensuring continued production of pVHL even when global cap-dependent translation is suppressed.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Organization

The pVHL protein is a small, predominantly alpha-helical protein that folds into two distinct structural domains: an N-terminal beta-sheet domain (residues 63–154) and a C-terminal alpha-helical domain (residues 155–213). The N-terminal 62 residues are intrinsically disordered and are not visible in most crystal structures. The high-resolution crystal structure of pVHL in complex with Elongin B and Elongin C (PDB: 1LM8) was a landmark achievement in understanding the molecular basis of oxygen sensing [<a href="#ref-1">1</a>]. This structure revealed that pVHL adopts a fold that is stabilized by its interaction with Elongin C, which binds to the alpha domain of pVHL via a conserved BC-box motif.

### 2.2 The Beta Domain: Substrate Recognition

The beta domain of pVHL (residues 63–154) is composed of seven anti-parallel beta-strands arranged in a beta-sandwich fold. This domain forms the primary substrate-binding surface. The key structural feature of this domain is a deep hydrophobic pocket that accommodates the hydroxylated proline residue of HIF-α. The pocket is lined by a set of highly conserved residues, including Tyr98, Ser111, His115, and Trp117. The hydroxyl group of hydroxyproline (Hyp564 in HIF-1α) forms a network of hydrogen bonds with the side chains of Ser111 and His115, while the pyrrolidine ring of the proline makes hydrophobic contacts with Tyr98 and Trp117. This precise complementarity ensures that only the hydroxylated form of HIF-α is recognized, providing the structural basis for the oxygen-dependence of the interaction.

The beta domain also contains a second, smaller binding pocket that has been shown to interact with the N-terminal transactivation domain (N-TAD) of HIF-α. This bipartite interaction increases the affinity and specificity of the pVHL-HIF-α interaction. Mutations that disrupt the beta domain, such as the frequently observed Tyr98His and Arg167Trp substitutions, abolish HIF-α binding and are strongly associated with the development of hemangioblastoma and ccRCC.

### 2.3 The Alpha Domain: Elongin C Binding and Complex Assembly

The alpha domain (residues 155–213) is composed of three alpha-helices that pack against each other to form a compact helical bundle. The primary function of this domain is to mediate the interaction with Elongin C, a component of the E3 ligase complex. The binding interface is formed by a conserved BC-box motif (residues 157–167) that adopts an extended conformation and inserts into a hydrophobic groove on the surface of Elongin C. The interaction is further stabilized by a network of electrostatic contacts involving residues Glu160, Asp162, and Arg167. Mutations in this domain, such as Leu188Val and Arg167Gln, disrupt Elongin C binding, leading to a failure to assemble the E3 ligase complex and consequent stabilization of HIF-α.

### 2.4 Post-Translational Modifications and Structural Dynamics

pVHL is subject to several post-translational modifications that modulate its function. Phosphorylation at Ser68 by the kinase CK2 has been shown to enhance the interaction between pVHL and Elongin C, thereby increasing E3 ligase activity. Conversely, phosphorylation at Tyr185 by Src family kinases has been reported to reduce pVHL's affinity for HIF-α, providing a mechanism for signal-dependent regulation of HIF-α stability. Acetylation of Lys171 by the acetyltransferase p300 has been shown to promote pVHL nuclear localization, while deacetylation by SIRT1 reverses this effect. These modifications add a layer of dynamic regulation to the oxygen-sensing pathway.

The intrinsically disordered N-terminal region of pVHL (residues 1–62) is not visible in the crystal structure but has been shown to mediate interactions with a variety of binding partners, including the microtubule network, the atypical protein kinase C (aPKC) complex, and the p53 tumor suppressor. This region also contains a nuclear export signal (NES) that regulates the subcellular localization of pVHL.

> **[Interactive 3D Protein Visualizer: Load VHL (PDB: 1LM8)](/tools/protein-structure-viewer?source=direct&pdbId=1LM8)**
>
> Use the interactive viewer to explore the atomic structure of pVHL in complex with Elongin B and Elongin C. Key residues for substrate binding (Tyr98, Ser111, His115, Trp117) and Elongin C binding (Arg167, Leu188) are highlighted. The beta domain is shown in blue, the alpha domain in red, and the BC-box motif in green. Rotate the structure to appreciate the spatial separation of the substrate-binding and complex-assembly surfaces.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Canonical HIF-α Degradation Pathway

The principal function of pVHL is to serve as the substrate recognition subunit of the CBCVHL E3 ubiquitin ligase complex. This complex is composed of pVHL, Elongin B, Elongin C, Cullin-2, and Rbx1. The assembly of this complex is initiated by the binding of pVHL to Elongin C, which in turn recruits Elongin B and Cullin-2. Rbx1, a RING finger protein, binds to Cullin-2 and recruits the E2 ubiquitin-conjugating enzyme. The fully assembled complex catalyzes the transfer of ubiquitin from the E2 enzyme to specific lysine residues on the substrate.

The substrate for this complex is the alpha subunit of Hypoxia-Inducible Factor (HIF-α). HIF-α exists in three isoforms: HIF-1α, HIF-2α, and HIF-3α. Under normoxic conditions, HIF-α is constitutively synthesized but rapidly degraded. The first step in this degradation process is the hydroxylation of specific proline residues within the oxygen-dependent degradation domain (ODDD) of HIF-α. This reaction is catalyzed by a family of prolyl hydroxylase domain enzymes (PHD1, PHD2, and PHD3), which require molecular oxygen, 2-oxoglutarate, and iron as cofactors. PHD2 is the primary enzyme responsible for hydroxylating HIF-1α under normoxic conditions. The hydroxylation of Pro402 and Pro564 in HIF-1α (and the corresponding prolines in HIF-2α and HIF-3α) creates a high-affinity binding site for the beta domain of pVHL.

The binding of hydroxylated HIF-α to pVHL is the rate-limiting step in the degradation pathway. Once bound, HIF-α is positioned in close proximity to the E2 enzyme, allowing for the processive transfer of ubiquitin to lysine residues on the surface of HIF-α. The polyubiquitinated HIF-α is then recognized by the 26S proteasome and degraded. The half-life of HIF-1α under normoxic conditions is less than 5 minutes, reflecting the efficiency of this degradation pathway.

### 3.2 Hypoxic Signaling and HIF-α Stabilization

Under hypoxic conditions, the activity of the PHD enzymes is suppressed due to the limited availability of molecular oxygen. Consequently, HIF-α is no longer hydroxylated and cannot bind to pVHL. This results in the stabilization and nuclear accumulation of HIF-α. In the nucleus, HIF-α heterodimerizes with the constitutively expressed aryl hydrocarbon receptor nuclear translocator (ARNT, also known as HIF-1β). The HIF-α/ARNT heterodimer binds to hypoxia response elements (HREs) in the promoter regions of target genes, driving their transcription.

The transcriptional program activated by HIF includes genes involved in:
- **Angiogenesis**: *VEGFA*, *PDGFB*, *ANGPTL4*
- **Glycolysis**: *LDHA*, *PKM*, *GLUT1* (SLC2A1)
- **Erythropoiesis**: *EPO*
- **Cell proliferation and survival**: *TGFα*, *IGF2*
- **pH regulation**: *CA9*, *CA12*

The inappropriate activation of this transcriptional program, due to loss of pVHL function, is the primary driver of the hypervascular phenotype characteristic of VHL-associated tumors.

### 3.3 HIF-Independent Functions of pVHL

While the HIF-α degradation pathway is the most well-characterized function of pVHL, a growing body of evidence indicates that pVHL has numerous HIF-independent functions that contribute to its tumor suppressor activity.

**Microtubule Stabilization**: pVHL binds directly to microtubules and protects them from depolymerization. This function is mediated by the N-terminal disordered region of pVHL and is independent of the E3 ligase activity. Loss of pVHL leads to microtubule destabilization, which contributes to genomic instability and aneuploidy.

**Primary Cilium Maintenance**: pVHL is required for the assembly and maintenance of the primary cilium, a microtubule-based organelle that functions as a cellular antenna for sensing extracellular signals. pVHL achieves this by stabilizing the microtubule axoneme of the cilium and by regulating the trafficking of proteins into the ciliary compartment. Loss of pVHL results in the absence of primary cilia, which is a common feature of ccRCC cells.

**Extracellular Matrix Remodeling**: pVHL regulates the expression and deposition of extracellular matrix (ECM) components, including fibronectin and collagen IV. pVHL-null cells fail to assemble a proper fibronectin matrix, which is associated with increased cell migration and invasion. This function is mediated, in part, through the regulation of the transcription factor *JUNB* and the matrix metalloproteinase *MMP1*.

**Regulation of p53 and NF-κB**: pVHL has been shown to interact with and stabilize the p53 tumor suppressor protein, enhancing its transcriptional activity. Additionally, pVHL negatively regulates the NF-κB signaling pathway by promoting the degradation of the NF-κB subunit p65 (RELA) and by inhibiting the activity of the IκB kinase (IKK) complex. These interactions link pVHL to broader cellular stress responses and apoptosis.

### 3.4 Protein-Protein Interaction Networks

The pVHL interactome is extensive and includes components of the ubiquitin-proteasome system, transcriptional regulators, and cytoskeletal proteins. High-throughput yeast two-hybrid and affinity purification-mass spectrometry studies have identified over 100 putative pVHL-interacting proteins. Key interactions include:

| **Interacting Protein** | **Function** | **Interaction Domain on pVHL** |
| :--- | :--- | :--- |
| Elongin C | E3 ligase complex assembly | Alpha domain (BC-box) |
| Elongin B | E3 ligase complex assembly | Indirect via Elongin C |
| Cullin-2 | E3 ligase scaffold | Indirect via Elongin C |
| HIF-1α, HIF-2α | Substrate for ubiquitination | Beta domain |
| p53 | Tumor suppressor stabilization | N-terminal region |
| aPKC (PRKCZ) | Cell polarity signaling | N-terminal region |
| Fibronectin | ECM assembly | N-terminal region |
| Vimentin | Intermediate filament | N-terminal region |
| SP1 | Transcription factor | N-terminal region |
| Jade-1 | Histone acetyltransferase complex | Beta domain |

The dynamic nature of these interactions is regulated by post-translational modifications of pVHL and by cellular context. For example, the interaction between pVHL and p53 is enhanced under conditions of DNA damage, while the interaction with HIF-α is strictly dependent on proline hydroxylation.

```mermaid
sequenceDiagram
    participant O2 as "Molecular Oxygen (O2)"
    participant PHD as "Prolyl Hydroxylase (PHD2)"
    participant HIF as "HIF-α (Cytosolic)"
    participant VHL as "pVHL (E3 Ligase Complex)"
    participant UB as "Ubiquitin (Ub)"
    participant PROT as "26S Proteasome"
    participant NUC as "Nucleus (HIF-α/ARNT)"
    O2->>PHD: Provides substrate for hydroxylation
    PHD->>HIF: Hydroxylates Pro402/Pro564
    HIF->>VHL: Binds via hydroxylated proline
    VHL->>UB: Polyubiquitination of HIF-α
    UB->>PROT: Recognition and degradation
    Note over HIF: Under Hypoxia, PHD is inactive
    Note over HIF: HIF-α escapes degradation
    HIF->>NUC: Translocates to nucleus
    NUC->>NUC: Heterodimerizes with ARNT
    NUC->>NUC: Binds HREs, activates transcription
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 The VHL Tumor Suppressor Gene and Mutation Spectrum

The *VHL* gene is a classic tumor suppressor, following Knudson's "two-hit" hypothesis. In hereditary VHL syndrome, patients inherit one mutated allele (germline mutation) and acquire a second somatic mutation or loss of heterozygosity (LOH) in the remaining wild-type allele. In sporadic ccRCC, both alleles are inactivated by somatic mutations, LOH, or promoter hypermethylation. The mutation spectrum of *VHL* is highly heterogeneous, with over 1,000 distinct germline and somatic mutations cataloged in the ClinVar and COSMIC databases.

### 4.2 Missense Mutations and Genotype-Phenotype Correlations

Missense mutations are the most common type of *VHL* mutation, accounting for approximately 50% of all pathogenic variants. These mutations cluster in specific regions of the protein, particularly within the beta domain (residues 63–154) and the alpha domain (residues 155–213). The location and nature of the missense mutation strongly influence the clinical phenotype.

**Type 1 VHL Disease** (high risk of ccRCC, low risk of pheochromocytoma) is typically associated with mutations that completely disrupt the folding or stability of pVHL, leading to a loss of all pVHL functions. These include truncating mutations, large deletions, and missense mutations that target residues critical for structural integrity, such as Cys162Phe and Arg167Trp.

**Type 2 VHL Disease** (high risk of pheochromocytoma, variable risk of ccRCC) is associated with missense mutations that partially retain some pVHL functions. Type 2A (low risk of ccRCC) is associated with mutations such as Tyr98His, which specifically disrupt HIF-α binding but preserve other functions. Type 2B (high risk of ccRCC) is associated with mutations such as Arg167Gln, which disrupt both HIF-α binding and Elongin C binding. Type 2C (pheochromocytoma only, no ccRCC or hemangioblastoma) is associated with mutations such as Leu188Val, which do not affect HIF-α regulation but disrupt other, less well-characterized functions of pVHL.

### 4.3 ClinVar Classification and Pathogenic Variants

The ClinVar database classifies *VHL* variants into five categories: pathogenic, likely pathogenic, uncertain significance, likely benign, and benign. As of the latest update, there are over 1,500 unique variants cataloged, with approximately 60% classified as pathogenic or likely pathogenic. The following table lists some of the most frequently reported pathogenic missense mutations:

| **Variant (Protein)** | **Variant (cDNA)** | **Domain** | **ClinVar Classification** | **Associated Phenotype** |
| :--- | :--- | :--- | :--- | :--- |
| Arg167Trp | c.499C>T | Alpha | Pathogenic | Type 1; ccRCC, hemangioblastoma |
| Arg167Gln | c.500G>A | Alpha | Pathogenic | Type 2B; ccRCC, pheochromocytoma |
| Tyr98His | c.292T>C | Beta | Pathogenic | Type 2A; pheochromocytoma, hemangioblastoma |
| Leu188Val | c.562C>G | Alpha | Pathogenic | Type 2C; pheochromocytoma only |
| Cys162Phe | c.485G>T | Alpha | Pathogenic | Type 1; ccRCC, hemangioblastoma |
| Ser111Asn | c.332G>A | Beta | Pathogenic | Type 2A; pheochromocytoma |
| Pro81Ser | c.241C>T | Beta | Likely pathogenic | Type 1; ccRCC |
| Asn78Ser | c.233A>G | Beta | Pathogenic | Type 1; ccRCC |

### 4.4 Somatic Mutations in Sporadic ccRCC

In sporadic ccRCC, the *VHL* gene is inactivated in up to 90% of cases. The mechanisms of inactivation include:
- **Intragenic mutations**: Present in ~50-60% of cases. These are predominantly missense and frameshift mutations, with a mutational spectrum that overlaps with the germline mutations seen in VHL syndrome.
- **Loss of heterozygosity (LOH)**: Deletion of the entire 3p arm is observed in ~90% of ccRCC cases, often in combination with an intragenic mutation in the remaining allele.
- **Promoter hypermethylation**: Silencing of the *VHL* promoter via CpG island methylation is observed in ~10-20% of cases and is mutually exclusive with intragenic mutations.

The presence of *VHL* mutations in ccRCC is associated with a specific gene expression signature characterized by upregulation of HIF target genes, including *VEGFA*, *CA9*, and *PDGFB*. This signature has been used to classify ccRCC tumors into molecular subtypes with distinct clinical outcomes.

### 4.5 Clinical Differentials and Diagnostic Considerations

The diagnosis of VHL syndrome is based on clinical criteria, which include the presence of characteristic tumors (hemangioblastoma, ccRCC, pheochromocytoma) and a family history of the disease. Genetic testing for *VHL* mutations is recommended for individuals who meet the clinical criteria or who have a family history of the syndrome. The differential diagnosis includes other hereditary cancer syndromes that predispose to renal cell carcinoma, such as:
- **Birt-Hogg-Dubé syndrome** (mutations in *FLCN*)
- **Hereditary leiomyomatosis and renal cell cancer** (mutations in *FH*)
- **BAP1 tumor predisposition syndrome** (mutations in *BAP1*)
- **MET-associated papillary renal cell carcinoma** (mutations in *MET*)

The distinction between these syndromes is important for clinical management, as the spectrum of tumors and the recommended surveillance protocols differ.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoproteins and pVHL

Several viral oncoproteins have been shown to interact with pVHL, either to subvert its function or to exploit it for viral replication. The most well-characterized interaction is with the human papillomavirus (HPV) E6 oncoprotein. The high-risk HPV types 16 and 18 encode E6, which binds to pVHL and promotes its ubiquitination and degradation via the E6AP ubiquitin ligase. This results in the stabilization of HIF-α and the activation of a hypoxic transcriptional program, which is thought to contribute to the hyperproliferative phenotype of HPV-infected epithelial cells.

The Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a viral G protein-coupled receptor (vGPCR) that has been shown to downregulate pVHL expression. This is achieved through the activation of the NF-κB pathway, which in turn represses *VHL* transcription. The resulting stabilization of HIF-α promotes the expression of VEGF and other angiogenic factors, contributing to the highly vascular nature of Kaposi's sarcoma lesions.

### 5.2 Bacterial Effectors and the Hypoxic Response

Certain bacterial pathogens have evolved mechanisms to manipulate the host hypoxic response. *Mycobacterium tuberculosis* has been shown to induce HIF-1α stabilization in infected macrophages, which is required for the intracellular survival of the bacterium. While the direct involvement of pVHL in this process is not fully established, it is likely that the bacterium modulates the activity of the PHD enzymes or pVHL itself to achieve HIF-1α stabilization.

*Salmonella enterica* serovar Typhimurium encodes a type III secretion system effector, SopE, which activates the host Rho GTPases and leads to the induction of HIF-1α. This induction is associated with increased bacterial replication and dissemination. The precise mechanism by which SopE affects pVHL function remains an area of active research.

### 5.3 Immune Evasion and pVHL

The loss of pVHL in ccRCC has been shown to have profound effects on the tumor immune microenvironment. pVHL-deficient tumors exhibit increased expression of the immune checkpoint ligand PD-L1, which is mediated by HIF-2α-dependent transcriptional activation of the *CD274* gene. This provides a mechanism by which pVHL loss allows tumor cells to evade T-cell-mediated immune surveillance. Additionally, pVHL loss leads to the secretion of immunosuppressive cytokines, such as [IL-10](/knowledge/bioinformatics/genes/immunology-checkpoints/il10-gene-structure-function-pathway) and TGF-β, which further dampen the anti-tumor immune response. These findings have important implications for the use of immune checkpoint inhibitors in the treatment of ccRCC.

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 Targeting the HIF-2α Pathway

The central role of HIF-2α in driving ccRCC tumorigenesis in the context of pVHL loss has made it an attractive therapeutic target. HIF-2α is a transcription factor that is difficult to target with traditional small-molecule inhibitors due to its lack of a deep binding pocket. However, the development of a new class of drugs that bind to the PAS-B domain of HIF-2α has revolutionized the treatment of ccRCC.

**Belzutifan (MK-6482, PT2977)** is a first-in-class, orally bioavailable small-molecule inhibitor of HIF-2α. It binds to the PAS-B domain of HIF-2α, inducing a conformational change that prevents the heterodimerization of HIF-2α with ARNT. This blocks the transcriptional activity of HIF-2α and inhibits the expression of downstream target genes, including *VEGFA*, *CCND1*, and *SLC2A1*. Belzutifan received FDA approval in August 2021 for the treatment of adult patients with VHL disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors. The approval was based on the results of a phase 2 clinical trial that demonstrated an objective response rate of 49% in patients with ccRCC and 30% in patients with pancreatic neuroendocrine tumors.

### 6.2 Anti-Angiogenic Therapies

The overexpression of VEGF, driven by HIF-α stabilization, is a hallmark of pVHL-deficient tumors. This has led to the development of anti-angiogenic therapies that target the VEGF signaling pathway.

**Sunitinib** and **Pazopanib** are multi-targeted receptor tyrosine kinase inhibitors that block the activity of VEGFR, PDGFR, and c-KIT. These agents were the standard of care for first-line treatment of metastatic ccRCC for many years. **Bevacizumab**, a monoclonal antibody that binds to VEGF-A and prevents its interaction with VEGFR, is also used in combination with interferon-alpha for the treatment of metastatic ccRCC.

### 6.3 mTOR Inhibitors

The PI3K/AKT/mTOR signaling pathway is frequently activated in ccRCC, in part due to the loss of pVHL. **Temsirolimus** and **Everolimus** are allosteric inhibitors of mTOR that have demonstrated clinical activity in ccRCC. These agents are used as second-line or later-line therapies for patients who have progressed on anti-angiogenic therapy.

### 6.4 Immune Checkpoint Inhibitors

The upregulation of PD-L1 in pVHL-deficient tumors has provided a rationale for the use of immune checkpoint inhibitors in ccRCC. **Nivolumab** (anti-PD-1) and **Ipilimumab** (anti-CTLA-4) have shown significant clinical activity in metastatic ccRCC and are now part of the standard treatment armamentarium. The combination of nivolumab and ipilimumab is a first-line treatment option for intermediate- and poor-risk metastatic ccRCC.

### 6.5 Emerging Therapeutic Strategies

Several novel therapeutic strategies are being explored for the treatment of pVHL-deficient tumors:

- **Prolyl Hydroxylase Mimetics**: Compounds that mimic the action of 2-oxoglutarate and inhibit PHD enzymes are being investigated for their potential to stabilize HIF-α in a controlled manner. While these agents are primarily being developed for the treatment of anemia, they may have applications in modulating the hypoxic response in cancer.
- **PROTACs (Proteolysis-Targeting Chimeras)**: The development of PROTACs that target HIF-2α for degradation is an area of active research. These bifunctional molecules would recruit an E3 ligase to HIF-2α, leading to its ubiquitination and proteasomal degradation.
- **Gene Therapy**: The delivery of a wild-type *VHL* gene to pVHL-deficient tumor cells using viral vectors is a theoretical approach that has been explored in preclinical models. While this approach faces significant challenges, including efficient delivery and sustained expression, it remains a potential avenue for future therapy.

## 7. Bioinformatic Resources & Database Accessions

The following table provides a comprehensive list of database accessions and resources for the *VHL* gene and its protein product.

| **Database** | **Accession / ID** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | 7428 | Gene-specific information, genomic context, and links to related resources |
| **Ensembl** | ENSG00000134086 | Genome annotation, transcript variants, and comparative genomics |
| **UniProt** | P40337 | Protein sequence, function, post-translational modifications, and structure |
| **RCSB PDB** | 1LM8 | Experimentally determined 3D structure of pVHL in complex with Elongin B and Elongin C |
| **ClinVar** | Variant IDs (e.g., VCV000012345) | Clinical significance of genetic variants |
| **COSMIC** | COSM12345 | Catalog of somatic mutations in cancer |
| **OMIM** | 193300 | Mendelian inheritance and phenotype of VHL syndrome |
| **HGNC** | 12687 | Gene symbol and nomenclature |
| **GeneCards** | GC03M010141 | Integrated gene information and functional annotations |
| **STRING** | P40337 | Protein-protein interaction networks |
| **BioGRID** | 112678 | Physical and genetic interactions |
| **PharmGKB** | PA37317 | Pharmacogenomic information and drug-gene associations |
| **GTEx** | VHL | Gene expression across human tissues |
| **Human Protein Atlas** | ENSG00000134086 | Protein expression and localization in human tissues |

### Gene Ontology (GO) Terms

| **Ontology** | **GO Term** | **Description** |
| :--- | :--- | :--- |
| **Molecular Function** | GO:0030332 | Cyclin binding |
| | GO:0005515 | Protein binding |
| | GO:0046872 | Metal ion binding |
| | GO:0061630 | Ubiquitin protein ligase activity |
| **Biological Process** | GO:0006511 | Ubiquitin-dependent protein catabolic process |
| | GO:0001666 | Response to hypoxia |
| | GO:0007049 | Cell cycle |
| | GO:0007018 | Microtubule-based movement |
| | GO:0030030 | Cell projection organization |
| **Cellular Component** | GO:0005737 | Cytoplasm |
| | GO:0005634 | Nucleus |
| | GO:0005813 | Centrosome |
| | GO:0005929 | Cilium |
| | GO:0031463 | Cul3-RING ubiquitin ligase complex |

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Stebbins, C. E., Kaelin, W. G., Jr, & Pavletich, N. P. (1999). Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. *Science*, 284(5413), 455–461. https://doi.org/10.1126/science.284.5413.455

<a id="ref-2"></a>[2] Kaelin, W. G., Jr. (2008). The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. *Nature Reviews Cancer*, 8(11), 865–873. https://doi.org/10.1038/nrc2502

<a id="ref-3"></a>[3] Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature*, 399(6733), 271–275. https://doi.org/10.1038/20459

<a id="ref-4"></a>[4] Jaakkola, P., Mole, D. R., Tian, Y. M., Wilson, M. I., Gielbert, J., Gaskell, S. J., von Kriegsheim, A., Hebestreit, H. F., Mukherji, M., Schofield, C. J., Maxwell, P. H., Pugh, C. W., & Ratcliffe, P. J. (2001). Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. *Science*, 292(5516), 468–472. https://doi.org/10.1126/science.1059796

<a id="ref-5"></a>[5] Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F. M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., & Geil, L. (1993). Identification of the von Hippel-Lindau disease tumor suppressor gene. *Science*, 260(5112), 1317–1320. https://doi.org/10.1126/science.8493574

<a id="ref-6"></a>[6] Chen, W., Hill, H., Christie, A., Kim